The Paradox Catalyst

Featured: RVMD, IBRX, CVX, XOM, VZ (Week of January 20-26, 2026)

Jan 27, 2026

∙ Paid

This week’s alternative data signals highlight surging interest in biotech innovations alongside energy sector asset recoveries, with mixed telecom sentiment amid service challenges.

CorMedix

Searches up 335% YoY driven by DefenCath’s 72% infection reduction data and Rezzayo acquisition. Phase III progress and leadership changes signal antimicrobial portf…

Continue reading this post for free, courtesy of Paradox Intelligence.

Or purchase a paid subscription.